Moreover, the anti-IL-5 antibody mepolizumab, already approved for asthma, has been the first drug specifically approved for the treatment of EGPA due to its inhibitory effect on various functions of eosinophils. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.